

July 27, 2023

Contents

Clinical Profile Documentation 2
 Curbside Connect..... 2
 Problem Groups..... 2
 Additions..... 2
 Lab Analytes & Panels..... 3
 Additions..... 3
 Medications..... 4
 Additions..... 4
 Updates..... 5
 Regimen Library..... 5
 Dexamethasone Premedication Update for Docetaxel Regimens..... 5
 Additions..... 6
 Updates..... 7
 Renames..... 7
 Research..... 8
 Updates..... 8
 Billing & HCPCS Codes 9
 Updates..... 9
 HCPCS & NDC Crosswalk..... 10
 Additions..... 10

Clinical Profile Documentation

Curbside Connect

This release includes content that helps enable new functionality in iKnowMed Generation 2. When a patient is facing a rare diagnosis, information regarding treatment experiences and insights can sometimes be hard to find. Curbside Connect can help by connecting you to subject matter experts on select rare cancer diagnoses.

After this release, you can access Curbside Connect for patients diagnosed with chronic lymphocytic leukemia (CLL) through the Problems tab.

To access Curbside Connect:

1. Open a patient chart and go to their Problems tab.
2. Edit the existing CLL problem or add a new one.
3. Click on the Details section in the left-hand column.
4. A new **Curbside Connect** item is displayed in the middle column (callout 1).
5. Use the **Click Here to Schedule** link to schedule a call with an Expert Connect physician to discuss your patient (callout 2).
6. Complete the information on the Curbside Connect page to book your appointment.

The screenshot displays the 'Problems' tab for a patient with 'Chronic lymphoid leukemia, disease (disorder)'. The interface is organized into three main columns:

- Left Column (Problem Details):** Includes fields for 'Problem (required)', 'Date of Diagnosis', 'Status' (Active), and 'Comment'. A 'Details' section is highlighted, showing ICD-10 codes (HCC C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission) and 'Additional Codes' (Problem does not have additional codes).
- Middle Column (Staging and Actions):** Contains a 'Staging' section with a '+ Add a Stage' button. Below it, a 'Stage Date' field is visible. A callout box (1) highlights a 'Curbside Connect with Dr. David Andorsky' link, and a callout box (2) highlights a 'CLICK HERE TO SCHEDULE' button.
- Right Column (Stage Date):** Features a 'Stage Date' field with a calendar icon and a text input field labeled 'Enter staging date'.

At the bottom right of the interface, there are three buttons: 'SAVE & CLOSE', 'CANCEL', and 'NEXT'.

Problem Groups

Additions

To support **Enhancing Oncology Model** required documentation of response to treatment, **Complete response to treatment** and **Partial response to treatment** are available documentation points for **Disease State** and **Disease Status**.

Lab Analytes & Panels

Additions

- Adenovirus F 40/41 PCR
- ANCA by IFA (RDL)
- Anti-dsDNA Ab by Farr (RDL)
- Anti-GBM Ab (RDL)
- Anti-MPO Ab (RDL)
- Anti-Nuclear Ab by IFA (RDL)
- Anti-PR-3 Ab (RDL)
- Auto CBC morphology
- B-cell receptor gene rearrangement (IGK) by PCR
- C3 complement (RDL)
- C4 complement (RDL)
- CALR variant
- Campylobacter PCR
- CBL variant
- CSF3R variant
- del(6q) CDKN2A FISH interpretation
- DPD gene mutation
- DPD gene mutation analysis panel
- DPYD genotype
- DPYD genotyping panel
- DPYD interpretation
- DPYD metabolic activity
- E. Coli (EAEC) PCR
- E. Coli (ETEC) PCR
- E. coli (STEC) stx1/stx2 PCR
- FISH, aggressive B-Cell lymphoma targetgene panel, PDF
- FISH, ALL adult targetgene panel, PDF
- FISH, AML targetgene panel, PDF
- FISH, CLL targetgene panel, PDF
- FISH, MDS targetgene panel, PDF
- FISH, MPN with eosinophilia targetgene panel
- FISH, MPN with eosinophilia targetgene panel, PDF
- FISH, myeloma targetgene panel, PDF
- FISH, plasma cell myeloma targetgene panel, PDF
- FISH, targetgene result
- FoundationOne PD-L1
- GAD-65 ab

- Glutamic acid decarboxylase (GAD) autoantibody
- Hemophilia A (Factor VIII) gene mutation panel
- Hemophilia A (Factor VIII) gene mutation sendout
- Insulin antibodies, uU/mL
- Insulin autoantibodies panel
- Notify IC comment
- Patient age
- Pregnenolone panel
- Pregnenolone, MS, ng/dL
- SETBP1 variant
- Shigella/E. coli (EIEC) PCR
- Stool pathogen panel by PCR
- Stool pathogen result by PCR
- Tempus PDL1 amendment panel
- Tempus xF amendment panel
- Tempus xT PD-L1-22C3 amendment panel
- Toxocara ab panel
- Toxocara ab, (IgG)
- Trichinella ab, (IgG)
- Trichinella spiralis ab, panel
- Urine culture comment
- Vasculitis profile (RDL) panel
- Vibrio Cholerae PCR
- Yersinia Enteroc PC

Medications

Additions

- ABSK121-NX invest Oral
- AK112 invest IV
- BLU-222 invest Oral
- CNTY-101 invest IV
- Dabigatran Oral Pellets
- LSTA1 invest IV
- Navtemadlin invest Oral
- NUC-3373 invest IV
- NXP800 invest Oral
- Ondansetron invest Oral
- RP-3500 invest Oral
- Rusfertide (PTG-300 invest) invest Subcutaneous Kit

- XB002 invest IV

Updates

Medication	Update
Aldesleukin Subcutaneous	New Dose Unit available: <ul style="list-style-type: none"> • million units
Dactinomycin IV	Updated Dose Units available: <ul style="list-style-type: none"> • mg/kg • mg Updated Rounding Rules available: <ul style="list-style-type: none"> • 10 mg Updated Max Single Dose (flat) available: <ul style="list-style-type: none"> • 3.125 mg Updated Instructions available: <ul style="list-style-type: none"> • Do not filter. Administer IV push over 2-3 minutes or infuse over 15-30 minutes. Dactinomycin is a vesicant.
IGM-8444 invest IV	New Form available: <ul style="list-style-type: none"> • 50 mg/10 mL (5 mg/mL) solution
PTG-300 invest Subcutaneous	New Brand Name available: <ul style="list-style-type: none"> • Rusfertide (PTG-300 invest) invest Subcutaneous Kit With the following Forms : <ul style="list-style-type: none"> • 10 mg recon soln kit • 20 mg recon soln kit • 30 mg recon soln kit • 45 mg recon soln kit • 60 mg recon soln kit
STRO-002 invest IV	New Brand Name available: <ul style="list-style-type: none"> • Luveltamab Tazevibulin invest (STRO-002 invest IV)

Regimen Library

Dexamethasone Premedication Update for Docetaxel Regimens

To improve ease of ordering and administering IV dexamethasone for patients who are non-adherent to PO dexamethasone, a pre-checked order for *as needed* IV dexamethasone is added to all docetaxel-containing regimens.

Regimens with *weekly* docetaxel now include a prescription order for reduced-dose PO dexamethasone administered the evening prior to, morning of, and evening after docetaxel. No changes will be made to PO dexamethasone dosing for regimens containing every 14-day, every 21-day, or every 28-day docetaxel.

Additions

Regimen Name	Diagnosis
Brentuximab vedotin + Nivolumab Q21D (DLBCL)	Lymphoma, Non-Hodgkin (NHL) (Parent)
Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Pertuzumab and Trastuzumab SQ (Phesgo) Q21D	Breast Cancer
Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel D1,8,15 + Pertuzumab and Trastuzumab SQ (Phesgo) Q21D	Breast Cancer
Gemcitabine D1,8 + Bevacizumab Q21D	Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer
Liposomal Irinotecan + Fluorouracil CIV D1-2 + Leucovorin + Oxaliplatin (NALIRIFOX) Q14D	Pancreatic Cancer
Obinutuzumab D1 fb Glofitamab-gxbm D8,15 fb D1 Q21D	Lymphoma, Non-Hodgkin (NHL) (Parent)
Pembrolizumab + Bevacizumab Q21D Maintenance (Cervical)	Cervical Cancer
Ribociclib + Anastrozole + Goserelin Q28D (Adjuvant)	Breast Cancer
Ribociclib + Anastrozole + Leuprolide Q28D (Adjuvant)	Breast Cancer
Ribociclib + Letrozole + Goserelin Q28D (Adjuvant)	Breast Cancer
Ribociclib + Letrozole + Leuprolide Q28D (Adjuvant)	Breast Cancer
Talazoparib + Enzalutamide + Goserelin Q28D	Prostate Cancer
Talazoparib + Enzalutamide + Leuprolide Q28D	Prostate Cancer
Talazoparib + Enzalutamide Q30D	Prostate Cancer

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Anal Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Leukemia, Chronic Lymphocytic (CLL)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) Parent
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer
- Primary Peritoneal Cancer
- Prostate Cancer
- Renal Pelvis and Ureter Cancer
- Sarcoma, Bone (Parent)
- Sarcoma, Soft Tissue (Parent)
- Solid Tumors (Parent) (including Solid Other/HL)
- Urethral Cancer
- Uterine Cancer (Parent)

Renames

Previous Name	New Name
Brentuximab vedotin + Nivolumab Q21D	Brentuximab vedotin + Nivolumab Q21D (HL)
Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) Q21D (Bevacizumab Continuation, Ovarian)	Bevacizumab (7.5 mg/kg) Q21D Maintenance (Ovarian)
Paclitaxel or Docetaxel + Carboplatin + Bevacizumab (15 mg/kg) Q21D (Bevacizumab Continuation, Ovarian, Uterine)	Bevacizumab (15 mg/kg) Q21D Maintenance (Ovarian, Uterine)

Research

Updates

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 20305	X			No longer available: USOR 20305 BAY 2416964 (PO;TID) + Pembrolizumab Q21D
USOR 20384	X			No longer available: USOR 20384 AMG 510 (PO; Daily) + Docetaxel Q21D USOR 20384 Part 2 Cohort D AMG 510 (PO; Daily) + Pemetrexed + Carboplatin Q21D USOR 20384 Part 2 Cohort D Pemetrexed + Pembrolizumab Maintenance Q21D
USOR 20396	X	X	X	
USOR 20398	X			Now available: USOR 20398 Inavolisib (PO; Daily) + Giredestrant (PO; Daily) Q28D USOR 20398 Inavolisib (PO; Daily) + Bevacizumab Q21D USOR 20398 Cyclophosphamide (PO; Daily) + Atezolizumab + Bevacizumab Q21D No longer available: USOR 20398 Trastuzumab Emtansine Q21D
USOR 20412	X	X		
USOR 21270	X	X		
USOR 21309	X		X	
USOR 21320	X	X	X	No longer available: USOR 21320 Osimertinib (PO; Daily) Q21D Now available: USOR 21320 Gemcitabine D1,8 + Carboplatin Q21D USOR 21320 Nab-Paclitaxel D1,8,15 + Carboplatin Q21D USOR 21320 Paclitaxel + Carboplatin Q21D USOR 21320 Pemetrexed + Carboplatin Q21D USOR 21320 Pemetrexed + Cisplatin Q21D
USOR 21353	X	X	X	
USOR 21356		X		
USOR 21389	X			

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 21456	X	X	X	
USOR 21538		X	X	
USOR 22003	X		X	
USOR 22018	X		X	Now available: USOR 22018 Physician's Choice Endocrine Therapy + Everolimus Q28D No longer available: USOR 22018 Exemestane (PO; Daily) + Everolimus (PO; Daily) Q28D
USOR 22151	X			

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Adalimumab-aacf	Q5131 per 1 startr pk
Adalimumab-adaz Subcutaneous	J3590 per 1 startr pk
Adalimumab-adaz Subcutaneous Pen Injector	J3590 per 1 startr pk
Adalimumab-adaz Subcutaneous Pen Injector Kit 80 mg/0.8 mL-40 mg/0.4 mL	J3590 per 1 startr pk
Adalimumab-adbm Subcutaneous Pen Injector Kit	J3590 per 1 dose pk
Adalimumab-aqvh (Yusimry)	J3590 per 40 mg
Adalimumab-fkjp (Hulio)	J3590 per 40 mg
Delandistrogene Moxeparvc-rokl (Elevidys)	J3590 per 200 mL
Glofitamab-gxbm IV	J3590 per 10 mg
Rezafungin (Rezzayo)	J3490 per 200 mg
Rozanolixizumab-noli (Rystiggo)	J3590 per 560 mg

HCPCS & NDC Crosswalk

Additions

Medication (Brand)	HCPCS Code	NDC
Bendamustine (Meitheal manufacture)	J9033 per 1 mg	71288010210 71288010320